Findings

What do systematic reviews say?

14 questions · 14 findings · 4 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 50%GRADE not reported 3 · 21.4%Very low 3 · 21.4%Low 0 · 0%Moderate 1 · 7.1%High 0 · 0%

Colchicine vs placebo or usual care

Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease

1 finding from 1 review

Colchicine for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 4412 participants
Moderate

Colchicine vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine vs no intervention

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine vs no intervention

Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine vs no intervention

Serious adverse events (proportion) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine vs no intervention

Serious adverse events (proportion) · people with primary biliary cholangitis

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Very low

Low‐dose colchicine vs NSAIDs

Serious adverse events · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose colchicine vs placebo

Serious adverse events · acute gout

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 133 participants
GRADE not reported

Colchicine vs no intervention

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose colchicine vs placebo

Serious adverse events · acute gout

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 111 participants
GRADE not reported

Colchicine plus standard care vs placebo or usual care

Serious adverse events ( · individuals with moderate or severe COVID‐19

1 finding from 1 review

Colchicine for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Very low

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (proportion) · people with primary biliary cholangitis

It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes serious adverse events (proportion) compared with UDCA (very low certainty).

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
OR 3.08 [0.12, 78.14]
1 study · 74 participants
Very low

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose colchicine

Serious adverse events · acute gout

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 126 participants
GRADE not reported